课题基金 / 基金详情

Identification of IL1RAP as an oncoprotein and candidate immunotherapeutic target in Ewing sarcoma

Identification of IL1RAP as an oncoprotein and candidate immunotherapeutic target in Ewing sarcoma
鉴定 IL1RAP 作为尤文肉瘤的癌蛋白和候选免疫治疗靶点
批准号：
396850
负责人：
Zhang Haifeng
金额：
$6.56万
依托单位：
BC Cancer, part of PHSA (Vancouver)
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-11-01 至 2020-11-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=396850&lang=en
关键词：
Biomarkers Cancer Therapeutic Targets Ewing Sarcoma Immunotherapy Mass Spectrometry Metastasis Translational Research

项目摘要

项目成果

Zhang Haifeng的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Ewing Sarcoma (EWS) is an aggressive form of childhood cancer that occurs on bone and soft tissue. Although conventional cancer therapeutic strategies, such as chemotherapy, radiation and surgery, have improved survival in patients with localized EWS tumo
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
High-risk neuroblastoma exploits Myosin 1B to reprogram the global secretome to drive tumor invasion and metastasis
海外基金